Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody

por Fallon, Jonathan K., Vandeveer, Amanda J., Schlom, Jeffrey, Greiner, John W.
Publicado 2017

Systemic immunotherapy of superficial mouse bladder cancer with Avelumab (MSB0010718C), an anti-PD-L1 immune checkpoint inhibitor

por Vandeveer, Amanda, Fallon, Jonathan, Tighe, Robert, Sabzevari, Helen, Schlom, Jeffrey, Greiner, John
Publicado 2015